Investing in Johnson & Johnson

Johnson & Johnson has been a part of people's lives for 126 years and a valuable part of their investments for more than 65 years. Founded in 1886, we listed our shares on the New York Stock Exchange for public investors in 1944.

During our history, we have built the most comprehensive base of health care businesses in the world, generating approximately 70 percent of our revenues from No. 1 or No. 2 global leadership positions in our respective markets.

Our consistent performance has enabled us to deliver an exceptional track record of growth that few, if any, companies can claim: 29 consecutive years of adjusted earnings increases; and 50 consecutive years of dividend increases. Over the last 10 years, Johnson & Johnson stock generated a 3.6 percent total return for investors compared to a 2.9 percent total return for the S&P 500.⁽¹⁾

E-Delivery of Annual Meeting and Proxy Materials

Johnson & Johnson is dedicated to improving the health and well-being of people everywhere. To fulfill this goal, we must protect the environments in which we work and live. A healthy planet and a healthy community go hand in hand. With this in mind, we now offer electronic versions of all of our company publications like the Annual Report.

Click here for the on-line Annual Report Click here for the Proxy Materials

   Additional Information

You can do your part as well. By reducing the amount of printed shareholder materials you receive, you can help protect the environment while quickly receiving important shareholder documents. In addition, reducing the printing and mailing costs associated with more traditional delivery methods allows us to control expenses in the interest of delivering more value for all our shareholders.

Registered Johnson & Johnson shareholders can sign up for electronic delivery of our reports and publications. Please go to www.computershare-na.com/green or contact our transfer agent, Computershare, at 1-800-328-9033.

Beneficial (owned through a broker/bank) Johnson & Johnson shareholders can register for on-line delivery of materials by clicking here and following the easy directions to your account.

Click here to see other financial documents and publications that can be electronically downloaded.

Investor News

May 9, 2012
Janssen Research & Development Submits Supplemental New Drug Application to U.S. FDA for XARELTO(R) (rivaroxaban) to Reduce the Risk of Stent Thrombosis in Patients with Acute Coronary Syndrome

May 2, 2012
Johnson & Johnson to Participate in 2012 Deutsche Bank Securities, Inc. 37th Annual Health Care Conference

May 2, 2012
Johnson & Johnson (China) Investment Ltd. Acquires Guangzhou Bioseal Biotech Co., Ltd.

Investor Communications

July 17, 2012 at 8:30 AM
Johnson & Johnson Second Quarter 2012 Earnings Conference Call

Financial Quick Links

Q1 2012 Earnings Announcement

Q1 2012 Sales of Key Products/Franchises

5 Year Financial Review

1. Data source - Bloomberg